12.12.2016 • TopicsBachem

Experts Statements: Dr. Ralph O. Schoenleber, Bachem

Despite tremendous challenges facing the pharmaceutical industry, it continues with its commitment to innovation and the discovery of novel drugs to address unmet medical needs. Indeed, medicinal chemists face a challenge of their own. Trying to survive in a changing environment where pharma is focusing on biologics drug candidates will require chemists to adapt.

Dr. Ralph O. Schoenleber, VP Research and Development, Bachem
Dr. Ralph O. Schoenleber, VP Research and Development, Bachem

CHEManager International asked R&D experts of chemical and pharmaceutical companies to elaborate on their research strategy and share their opinion with our readers. In detail, we interviewed professionals ranging from CEOs to heads of R&D and process development about:

The crucial success factors in chemical and pharmaceutical research.

Dr. Ralph O. Schoenleber: ŒFor a contract manufacturing organization in the competitive environment of the pharma and biotech industry, research and development is extremely important to further enhance customer satisfaction and service quality. Constantly increasing demands on performance combined with growing sustainability requirements, such as those relating to occupational safety as well as waste management, are chief concerns of our markets. There is a continuous trend toward the development of molecules with higher complexity, and at the same time, the patent landscape is more and more crowded. Furthermore, requirements from customers and authorities with regard to documentation in general and data integrity in particular are changing the way people work.

 

Fostering a culture that encourages the sharing of information …
is a fundamental requirement.

 

Challenges and changes affecting the work of R&D chemists in the future.

Dr. Ralph O. Schoenleber:Ž In order to meet the increasing demands of the markets, a company needs the right combination of creative, innovative, but at the same time structured and accurately working scientists on board, and to put a focus on the management of knowledge as a key factor to success. Efforts on knowledge management at Bachem focus on organizational objectives, such as continuous improvement, competitive advantage, innovation, and the sharing of lessons learned. Knowledge management includes expert systems, post-action reviews, cross-project learning, knowledge sharing, best-practice transfer, and collaborative software technologies — e.g., chemistry and technology forums including blogs. Fostering a culture that encourages the sharing of information, based on the concept that knowledge is not irrevocable and should be shared and updated to remain relevant, is a fundamental requirement for successful and future-oriented research and development.

Company

Logo:

Bachem

Hauptstr. 144
4416 Bubendorf
Switzerland

Company contact







Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
19.03.2025 • TopicsStrategy

The Future of Demand for Chemicals

The chemical industry is shifting to sustainability-related products, with demand growing 4.5 times faster than conventional ones. Companies must revise their market strategies to capitalize on this opportunity.

Photo
14.05.2025 • TopicsPharma

Pharma Outlook 2025

The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.